Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27962426 | 0.87 | F2 (0.45) | F2F10LMNAKMT2AKDM4E | |
| SCHEMBL16681778 | 0.85 | F2 (0.48) | F2F10GABBR2GABBR1LMNA | |
| SCHEMBL7871985 | 0.85 | SLC6A3 (0.44) | F2F10LMNATSHRKDM4E | |
| SCHEMBL4408370 | 0.82 | F2 (0.52) | F2F10GABBR2GABBR1LMNA | |
| SCHEMBL393911 | 0.82 | GABBR2 (0.58) | F2F10GABBR2GABBR1LMNA | |
| Hydrochloric Acid SCHEMBL7137209 | 0.81 | GABBR2 (0.60) | F2F10GABBR2GABBR1LMNA | |
| SCHEMBL5848181 | 0.81 | F2 (0.45) | F2F10GABBR2GABBR1LMNA | |
| SCHEMBL27671897 | 0.79 | GABBR2 (0.65) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL10908208 | 0.79 | ALDH1A1 (0.51) | GABBR2GABBR1LMNACYP2C9CYP3A4 | |
| SCHEMBL657923 | 0.78 | MAPT (0.46) | F2F10GABBR2GABBR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497287-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2231589-B1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8314128-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101791-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231589-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076399-A2 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040965-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | F2 2523/4885F10 2515/4885GABBR2 908/4885 |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | F2 2523/4885F10 2515/4885GABBR2 908/4885 |
| US-20120088794-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | F2 2523/4885F10 2515/4885GABBR2 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.